biostudies-literatureBarry ANational Center for Advancing Translational SciencesNCATS NIH HHSNICHD NIH HHSNIA NIH HHSAlzheimer's Disease Research Centers ProgramNational Centralized Repository for Alzheimer Disease and Related DementiasNational Institute on Aging and the National Institute for Child Health and Human DevelopmentDS-Connecte70211https://www.ebi.ac.uk/biostudies/studies/S-EPMC12035545biostudies-literatureUnknown21(4)<h4>Introduction</h4>Gait abnormalities are associated with Alzheimer's disease (AD) in the general population, but it is unclear if the same is true for individuals with Down syndrome (DS). This study examined gait across 32 months in relation to neuroimaging biomarkers (amyloid beta [Aβ], neurofibrillary tangles [NFTs], and hippocampal volume), cognitive decline, and clinical AD status in adults with DS.<h4>Methods</h4>Participants were 218 adults with DS who underwent Aβ and NFT positron emission tomography (PET) and magnetic resonance imaging (MRI) scans, cognitive testing, and gait assessments at baseline and 32 months. Residual change regression models were conducted.<h4>Results</h4>Higher baseline Aβ PET and NFT PET and lower MRI hippocampal volume were associated with gait declinesAlzheimer's & dementia : the journal of the Alzheimer's AssociationLongitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome.PMC12035545U24 AG21886P50 AG008702UL1 TR002373UL1 TR001873UL1 TR002345P30 AG062421U54 HD087011UL1 TR001414P50 AG005681P50 HD105353U19 AG068054P50 AG005133UL1 TR001857P30 AG062715P30 AG066519U01 AG051412U01 AG051406P50 AG16537U54 HD090256RO1 AG070028Barry ALai FHom CLMinhas DAnces BMAlzheimer Biomarker Consortium ‐ Down syndromeZaman SHLott IHanden BLLee JHMapstone MPrice JChristian BTKrinsky-McHale SJGlueck AHarp JZammit MLaymon CSchmitt FClare ICHCohen AHartley SLBolt DLuo WRosa HDPulsifer MHead EPeven JCfalseLongitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome.<h4>Introduction</h4>Gait abnormalities are associated with Alzheimer's disease (AD) in the general population, but it is unclear if the same is true for individuals with Down syndrome (DS). This study examined gait across 32 months in relation to neuroimaging biomarkers (amyloid beta [Aβ], neurofibrillary tangles [NFTs], and hippocampal volume), cognitive decline, and clinical AD status in adults with DS.<h4>Methods</h4>Participants were 218 adults with DS who underwent Aβ and NFT positron emission tomography (PET) and magnetic resonance imaging (MRI) scans, cognitive testing, and gait assessments at baseline and 32 months. Residual change regression models were conducted.<h4>Results</h4>Higher baseline Aβ PET and NFT PET and lower MRI hippocampal volume were associated with gait declines2025-01-01T00:00:00Z2025 Apr2025-07-11T03:03:48.962Z2025-07-11T03:03:48.962ZS-EPMC120355454028984410.1002/alz.70211